Gastric cancer in Europe: European union network of excellence (EUNE) for gastric cancer steering group

British Journal of Surgery

Volumn 95, Issue 4, 2008, Pages 406-408

  Allum, W H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; UVOMORULIN; BIOLOGICAL PRODUCT;

CANCER STAGING; EUROPE; FUNDING; HEALTH CARE ORGANIZATION; HUMAN; HUMAN TISSUE; JAPAN; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; SHORT SURVEY; STANDARDIZATION; STOMACH CANCER; SURGICAL APPROACH; TREATMENT OUTCOME; ARTICLE; STOMACH TUMOR;

BIOLOGICAL PRODUCTS; EUROPE; HUMANS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 41949118106     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6197     Document Type: Short Survey

References (11)

1. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I et al.; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
2. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V et al. Patient survival after D1 and D2 resections for gastric cancer: long term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
3. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-1732.
4. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ; German Gastric Carcinoma Study Group. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993; 80: 1015-1018.
5. Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MR, McMahon MJ et al. Gastric cancer: a curable disease in Britain. BMJ 1993; 307: 591-596.
6. McCulloch P, Nita ME, Kazi H, Gama Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003; (4)CD001964.
7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
8. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25(Suppl): 4510.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A et al.; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
11. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459.